BREYANZI® (lisocabtagene maraleucel) is a CD19-directed, genetically modified, autologous T-cell immunotherapy for adult patients with certain types of lymphoma. See response rates and safety profile. Please see Important Safety Information including Boxed WARNINGS.
No named decision-maker yet.
No careers mailbox known
HydroCision helps improve clinical outcomes by adapting its FluidJet technology for spine & orthopedic applications through the SpineJet and TenJet devices.
Thomas Abert · Executive Officer · decision-maker
Richard Lytle Iii · Executive Officer, Director · decision-maker
Paul Kowalski · Executive Officer · decision-maker
Patricia Vanblarcom · Executive Officer · decision-maker
Careers mailbox is known
Nov 15, 2024
Raised a round Venture round $2.5M · SEC Form D
Mar 5, 2019
New executive HydroCision Appoints Medical Device Executive with Global Commercial and Market Development Experience as New CEO · markets.businessinsider.com
Learn about BLINCYTO® (blinatumomab), a treatment for adults and children with CD-19 positive B-cell precursor acute lymphoblastic leukemia (BCP-ALL), including how it works and what to expect.
No named decision-maker yet.
No careers mailbox known